Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (NASDAQ:RNA), as an independent member of its Board of Directors. Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum's board. Ms. Boyce has extensive expertise in global pharmaceut

PhenomeX to begin trading under symbol (NASDAQ:CELL) EMERYVILLE, Calif., March 21, 2023 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a life sciences tools company, today announced that it has completed its previously announced acquisition of IsoPlexis Corporation (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health. The newly combined company has been renamed PhenomeX and its common stock will begin trading on Nasdaq under the ticker symbol "CELL" at market open tomorrow. PhenomeX is positioned to be the leading

EMERYVILLE, Calif., Feb. 23, 2023 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a life sciences tools company, today reported financial results for the fourth quarter and full year ended December 31, 2022. Recent Highlights Achieved revenue of $78.6 million for the full year 2022, representing an 8% decrease over the prior year;Announced the acquisition agreement of IsoPlexis to create a premier functional cell biology company, PhenomeX, when the merger closes, would accelerate the transformation of Berkeley Lights from a technology platform company into a growing, profi

EMERYVILLE, Calif., Feb. 13, 2023 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a life sciences tools company, today announced that the Company will be reporting financial results for the fourth quarter and full year 2022 after market on Thursday, February 23, 2023. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.   Live audio of the webcast will be available on the "Investors" section of the Company's website at www.berkeleylights.com. The webcast will be archived and available for replay

EMERYVILLE, Calif., Jan. 9, 2023 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a life sciences tools company, today announced preliminary unaudited revenue results for the full year ended December 31, 2022. Total revenue for the full year 2022 is expected to be in the range of $78.0 million to $78.5 million, compared to $85.4 million in 2021. Results were lower-than-expected due to a delay in several Beacon® platform placements, which are now expected in 2023, and lower revenue from partnership and services contracts. During fourth quarter 2022, we observed a tightening

New, two-chip, single-cell optofluidic system ideal for small- to mid-sized biopharma & CDMOs/CROs to affordably gain access to the Beacon® technology and cell line development-specific applications EMERYVILLE, Calif., Jan. 9, 2023 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a life sciences tools company, today announced the launch of the Beacon Select™, the company's new optofluidic system for cell line development (CLD). The Beacon Select builds upon the same cutting-edge technology offered by the original Beacon system launched in 2017 that currently has an installed base of more than 130 systems globally. The Beacon Select offers customers optofluidic and NanoPen® chamber technol

EMERYVILLE, Calif., Jan. 3, 2023 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a life sciences tools company, today announced the Company will be participating in the upcoming 41st Annual J.P. Morgan Healthcare Conference. Berkeley Lights management is scheduled to present and participate in a Q&A session on Thursday, January 12 at 11:15 a.m. Pacific Time / 2:15 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the company website at www.berkeleylights.com. About Berkeley LightsBerkeley Lights i

Complementary Technologies, Customer Bases, and Commercial Channels to Strengthen Leadership in High-Growth, Single-Cell Biology Significant Cost Synergies to Increase Profitability and Accelerate Breakeven Horizon in 2024, Earlier Than Berkeley Lights Expected as a Standalone Entity Companies to Host Joint Conference Call and Webcast Today at 5:00 p.m. ET EMERYVILLE, CA and BRANFORD, Conn., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Berkeley Lights (NASDAQ:BLI), a life sciences tools company, and IsoPlexis (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced a definitive agreement under which Berkeley Lights will acquire

Complementary Technologies, Customer Bases, and Commercial Channels to Strengthen Leadership in High-Growth, Single-Cell Biology Significant Cost Synergies to Increase Profitability and Accelerate Breakeven Horizon in 2024, Earlier Than Berkeley Lights Expected as a Standalone Entity Companies to Host Joint Conference Call and Webcast Today at 5:00 p.m. ET EMERYVILLE, Calif. and BRANFORD, Conn., Dec. 21, 2022 /PRNewswire/ -- Berkeley Lights (NASDAQ:BLI), a life sciences tools company, and IsoPlexis (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced a definitive agreement under which Berkeley Lights will acquire IsoP

EMERYVILLE, Calif., Nov. 30, 2022 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a leader in digital cell biology, today announced its participation at the upcoming Antibody Engineering & Therapeutics (AE&T) meeting, being held from December 4 - 8, 2022, in San Diego, California. During the AE&T meeting, the latest antibody science, technologies, and academic and industry partners come together to accelerate next-generation antibodies towards commercial success. Berkeley Lights will showcase its Beacon® Optofluidic System and single B-cell antibody discovery workflows at

SC 13G/A - Bruker Cellular Analysis, Inc. (0001689657) (Subject)

SC 13G - PhenomeX Inc. (0001689657) (Subject)

SC 13G/A - PhenomeX Inc. (0001689657) (Subject)

SC 13G - PhenomeX Inc. (0001689657) (Subject)

SC 13G - Berkeley Lights, Inc. (0001689657) (Subject)

SC 13G/A - Berkeley Lights, Inc. (0001689657) (Subject)

SC 13G/A - Berkeley Lights, Inc. (0001689657) (Subject)

SC 13G - Berkeley Lights, Inc. (0001689657) (Subject)

SC 13G/A - Berkeley Lights, Inc. (0001689657) (Subject)

SC 13G/A - Berkeley Lights, Inc. (0001689657) (Subject)

4 - Bruker Cellular Analysis, Inc. (0001689657) (Issuer)

4 - Bruker Cellular Analysis, Inc. (0001689657) (Issuer)

4 - Bruker Cellular Analysis, Inc. (0001689657) (Issuer)

4 - Bruker Cellular Analysis, Inc. (0001689657) (Issuer)

4 - Bruker Cellular Analysis, Inc. (0001689657) (Issuer)

4 - Bruker Cellular Analysis, Inc. (0001689657) (Issuer)

4 - Bruker Cellular Analysis, Inc. (0001689657) (Issuer)

4 - Bruker Cellular Analysis, Inc. (0001689657) (Issuer)

4 - Bruker Cellular Analysis, Inc. (0001689657) (Issuer)

4 - Bruker Cellular Analysis, Inc. (0001689657) (Issuer)

EMERYVILLE, Calif., Feb. 23, 2023 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a life sciences tools company, today reported financial results for the fourth quarter and full year ended December 31, 2022. Recent Highlights Achieved revenue of $78.6 million for the full year 2022, representing an 8% decrease over the prior year;Announced the acquisition agreement of IsoPlexis to create a premier functional cell biology company, PhenomeX, when the merger closes, would accelerate the transformation of Berkeley Lights from a technology platform company into a growing, profi

EMERYVILLE, Calif., Feb. 13, 2023 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a life sciences tools company, today announced that the Company will be reporting financial results for the fourth quarter and full year 2022 after market on Thursday, February 23, 2023. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.   Live audio of the webcast will be available on the "Investors" section of the Company's website at www.berkeleylights.com. The webcast will be archived and available for replay

EMERYVILLE, Calif., Jan. 9, 2023 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a life sciences tools company, today announced preliminary unaudited revenue results for the full year ended December 31, 2022. Total revenue for the full year 2022 is expected to be in the range of $78.0 million to $78.5 million, compared to $85.4 million in 2021. Results were lower-than-expected due to a delay in several Beacon® platform placements, which are now expected in 2023, and lower revenue from partnership and services contracts. During fourth quarter 2022, we observed a tightening

Complementary Technologies, Customer Bases, and Commercial Channels to Strengthen Leadership in High-Growth, Single-Cell Biology Significant Cost Synergies to Increase Profitability and Accelerate Breakeven Horizon in 2024, Earlier Than Berkeley Lights Expected as a Standalone Entity Companies to Host Joint Conference Call and Webcast Today at 5:00 p.m. ET EMERYVILLE, CA and BRANFORD, Conn., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Berkeley Lights (NASDAQ:BLI), a life sciences tools company, and IsoPlexis (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced a definitive agreement under which Berkeley Lights will acquire

Complementary Technologies, Customer Bases, and Commercial Channels to Strengthen Leadership in High-Growth, Single-Cell Biology Significant Cost Synergies to Increase Profitability and Accelerate Breakeven Horizon in 2024, Earlier Than Berkeley Lights Expected as a Standalone Entity Companies to Host Joint Conference Call and Webcast Today at 5:00 p.m. ET EMERYVILLE, Calif. and BRANFORD, Conn., Dec. 21, 2022 /PRNewswire/ -- Berkeley Lights (NASDAQ:BLI), a life sciences tools company, and IsoPlexis (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced a definitive agreement under which Berkeley Lights will acquire IsoP

EMERYVILLE, Calif., Nov. 8, 2022 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a leader in digital cell biology, today reported financial results for the quarter ended September 30, 2022. Recent Highlights Delivered total revenue of $21.4 million for the third quarter of 2022, representing a decrease of 12% compared to the third quarter of 2021 and an increase of 12% compared to the second quarter of 2022Achieved record recurring revenue of $7.0 million, an increase of 48% year over year and an increase of 18% compared to second quarter of 2022Delivered gross margin of 7

EMERYVILLE, Calif., Oct. 18, 2022 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a leader in digital cell biology, today announced that the Company will be reporting financial results for the third quarter 2022 after market on Tuesday, November 8, 2022. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.  Live audio of the webcast will be available on the "Investors" section of the Company's website at www.berkeleylights.com. The webcast will be archived and available for replay after the even

Company outlines near-term strategic plan to generate positive operating cashflow by early 2025 EMERYVILLE, Calif., Aug. 9, 2022 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a leader in digital cell biology, today reported financial results for the quarter ended June 30, 2022. Financial HighlightsDelivered total revenue of $19.2 million for the second quarter of 2022, representing a decrease of 1% compared to the second quarter of 2021Achieved recurring revenue of $5.9 million, an increase of 50% year over yearDelivered gross margin of 67% for the second quarter of 2022

EMERYVILLE, Calif., July 21, 2022 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a leader in digital cell biology, today announced that the Company will be reporting financial results for the second quarter 2022 after market on Tuesday, August 9, 2022. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.   Live audio of the webcast will be available on the "Investors" section of the Company's website at www.berkeleylights.com. The webcast will be archived and available for replay after the even

EMERYVILLE, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc. (NASDAQ:BLI), a leader in digital cell biology, today reported financial results for the quarter ended March 31, 2022. Recent Highlights Delivered total revenue of $20.2 million for the first quarter of 2022, representing growth of 8.5% year over yearSigned a strategic partnership agreement with Vestaron to develop pesticidal peptides using the Company's Beacon® platform and proprietary high-throughput, functional screening service Released an upgrade to the Software Suite for Beacon and Lightning® platforms, enabling customers to gain easier insights and faster throughput operations for antibody discovery, cell l

Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (NASDAQ:RNA), as an independent member of its Board of Directors. Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum's board. Ms. Boyce has extensive expertise in global pharmaceut

EMERYVILLE, Calif., Sept. 19, 2022 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a leader in digital cell biology, today announced that Scott Chaplin has been named the Company's chief legal officer and corporate secretary, effective immediately. Mr. Chaplin will have overall responsibility for the corporate legal function, including contracts, governance, compliance and management of its extensive intellectual property and patent portfolio. As chief legal officer, he will serve as an adviser to the chief executive officer (CEO), Board of Directors, and senior management members.

EMERYVILLE, Calif., Aug. 1, 2022 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a leader in digital cell biology, today announced that Rolando Brawer, Ph.D. has been named executive vice president, Strategy & Corporate Development, effective immediately. In this newly created role, Dr. Brawer will lead Berkeley Lights' strategy and corporate development functions and support the Company's growth strategy through identification, assessment and execution of potential mergers, acquisitions, investments, licensing agreements, joint ventures and more. "We are thrilled to welco

EMERYVILLE, Calif., April 13, 2022 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc. (NASDAQ:BLI), a leader in digital cell biology, announced the appointment of Lucas Vitale to the newly created role of Chief Human Resources Officer ("CHRO"), effective immediately. Vitale will lead Berkeley Lights' Human Resources function. He will report directly to the Company's Chief Executive Officer (CEO), Dr. Siddhartha Kadia. As Berkeley Lights' newly appointed CEO, Dr. Kadia is focused on the further development of its human capital and talent function to support the Company's growth opportunities. Over his 20-year career in the life sciences industry, Vitale has gained extensive expertise across all a

EMERYVILLE, Calif., March 09, 2022 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc. (NASDAQ:BLI) ("Berkeley Lights" or the "Company") a leader in digital cell biology, today announced it has appointed Dr. Siddhartha Kadia as its new chief executive officer (CEO), effective immediately. Dr. Kadia succeeds Eric D. Hobbs, Ph.D., as part of the previously announced leadership transition. Dr. Kadia will remain a member of the Berkeley Lights Board of Directors. Dr. Kadia is an accomplished executive, bringing more than two decades of relevant industry and leadership experience as well as significant expertise in globally commercializing disruptive life science technologies and services. Previously,

EMERYVILLE, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc., (NASDAQ:BLI), ("BLI" or "the Company"), a leader in digital cell biology, today announced that Eric D. Hobbs, Ph.D. will transition from his role as chief executive officer (CEO) and member of the board of directors to president of the Antibody Therapeutics business line. The Company is initiating a search for a new CEO as it continues to execute on its business strategy, including the successful addition of services to its portfolio of product offerings. Dr. Hobbs will continue to serve in his role as CEO and member of the board of directors until the appointment of his successor. Dr. Hobbs joined the Company in

EMERYVILLE, Calif., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc. (NASDAQ:BLI), a leader in digital cell biology, today announced the appointment of Jessica Hopfield, Ph.D. to the Berkeley Lights' Board of Directors as an independent director, effective December 15, 2021. "Dr. Hopfield is a respected and accomplished industry veteran, and we are thrilled to welcome her to our Board," said Eric Hobbs, Ph.D., chief executive officer of Berkeley Lights. "With more than two decades of medical device, biotech and pharmaceutical experience, Dr. Hopfield brings to Berkeley Lights valuable strategic insight and a strong focus on performance to drive our unrivaled ability to understand c

EMERYVILLE, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc. (NASDAQ:BLI), a leader in digital cell biology, today announced that Siddhartha Kadia, Ph.D. joined the Berkeley Lights Board of Directors as an independent director, effective September 7, 2021. "I am excited to join the Berkeley Lights Board of Directors," said Dr. Kadia. "I am passionate about technologies that can transform the life science industry and the Berkeley Lights platform is incredibly powerful, with value across a wide range of applications and markets. I look forward to helping the company deliver on its long-term strategies." "Siddhartha brings to Berkeley Lights extensive global leadership expe

15-12G - Bruker Cellular Analysis, Inc. (0001689657) (Filer)

POSASR - Bruker Cellular Analysis, Inc. (0001689657) (Filer)

S-8 POS - Bruker Cellular Analysis, Inc. (0001689657) (Filer)

S-8 POS - Bruker Cellular Analysis, Inc. (0001689657) (Filer)

S-8 POS - Bruker Cellular Analysis, Inc. (0001689657) (Filer)

S-8 POS - Bruker Cellular Analysis, Inc. (0001689657) (Filer)

S-8 POS - Bruker Cellular Analysis, Inc. (0001689657) (Filer)

25-NSE - Bruker Cellular Analysis, Inc. (0001689657) (Subject)

8-K - PhenomeX Inc. (0001689657) (Filer)

SC TO-T/A - PhenomeX Inc. (0001689657) (Subject)

Morgan Stanley downgraded Berkeley Lights from Equal-Weight to Underweight and set a new price target of $5.00 from $10.00 previously

BTIG Research downgraded Berkeley Lights from Buy to Neutral

JP Morgan downgraded Berkeley Lights from Overweight to Neutral and set a new price target of $8.00 from $12.00 previously

Cowen resumed coverage of Berkeley Lights with a rating of Outperform

Morgan Stanley reiterated coverage of Berkeley Lights with a rating of Equal-Weight and set a new price target of $14.00 from $20.00 previously

Morgan Stanley reiterated coverage of Berkeley Lights with a rating of Equal-Weight and set a new price target of $20.00 from $36.00 previously

Stifel downgraded Berkeley Lights from Buy to Hold and set a new price target of $12.00 from $61.00 previously

William Blair downgraded Berkeley Lights from Outperform to Mkt Perform

Stifel downgraded Berkeley Lights from Hold to Sell and set a new price target of $12.00 from $61.00 previously

Cowen resumed coverage of Berkeley Lights with a rating of Outperform